DTG50+ FTC200+ TAF25mg tab/PAC-90 No CTN

General description:
Dolutegravir 50mg + Emtricitabine 200mg + Tenofovir Alafenamide (TAF) 25mg tablets, bottle pack of 90 without outer carton.

Technical Specifications
Each film coated tablet contains Dolutegravir 50mg + Emtricitabine 200mg + Tenofovir Alafenamide Fumarate equivalent to 25mg of Tenofovir Alafenamide (TAF) as fixed dose combination (FDC).

Therapeutic class
Dolutegravir is an Integrase Inhibitor
Emtricitabine is a Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Tenofovir is a Nucleotide Reverse Transcriptase Inhibitor (NtRTI)

Dosage, Instructions for use: For more details, please see WHO treatment guidelines www.who.int/hiv/pub/guidelines/en/index.html and WHO Essential Medicines Library www.who.int/emlib/ or your regional/national guidelines.

Details about paediatric dosage schemes can be found at http://www.who.int/hiv/ topics/paediatric/en/index.html

WHO generic tool for assessing paediatric ARV dosing
http://www.w ho.int/hiv/paediatric/generictool/en/

Indications
Management of HIV-1 infection in children and adults in combination with at least two other antiretroviral drugs. By mouth (oral) PO.

Shelf life: 24 months

Storage conditions:
Store at 20º to 25º C; Excursions permitted to 15 - 30ºC.

Component of a KIT: No

Other available formulations
The product may also be available in other formulations, pack sizes, or in combinations with other ARVs.